Q3FY2025 Performance Highlights Revenue at ₹11,537m, grew 14.6% YoY Gross margin at ₹6,735m, grew 25.1% YoY EBITDA grew 46.9% YoY to ₹2,103m with EBITDA margin at 18.2%, grew 401bps YoY US revenue at $73m, grew 13.7% YoY Q3FY25 Reported PAT at ₹900m Reported
Scored 85/100, 2.3x the industry average in Social Scored 73/100, 1.8x the industry average in Governance Scored 62/100, 1.8x the industry average in Environment Strides Pharma Science Limited is pleased to announce that the Company has received an ESG score of 76/100 and CSA score of 75/100
Q1FY2025 Performance Highlights Revenues at ₹10,875m, Grew 16.7% YoY in line with FY25 Outlook Gross Margin improved by 264bps YoY to 61.3% EBITDA grew by 28.7% YoY to ₹2,170m with EBITDA margin at 20%, a growth of 187bps YoY US revenues at a historic
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation Approval bolsters Strides’ portfolio for the US by adding another differentiated and niche product with limited competition Strides Pharma Science Limited (Strides) today announced that its step-down wholly
